with ESL was shown to be non-inferior to twice-daily monotherapy with controlled-release carbamazepine. 2 These findings are supported by the results of two phase III withdrawal to monotherapy trials, 3, 4 which resulted in approval for ESL in the monotherapy setting in the United States. 5 Clinical trials are essential for the development and approval of new AEDs, but due to the strict inclusion and exclusion criteria typically employed, they may not always represent the entire breadth of patient types encountered in clinical practice. 6, 7 Furthermore, individualized treatment approaches are used in clinical practice, and protocol-defined dosing strategies may restrain assessment of this in clinical trials. Therefore, clinical practice studies complement evidence from clinical trials by further elucidating an agent's effectiveness when used under everyday conditions.
The Euro-Esli study addressed the need for clinical practice data by conducting an audit of clinical practice studies conducted across Europe, thereby providing insights into how the evidence obtained from ESL clinical trials has translated into the clinical practice setting. 8 Euro-Esli represents the largest study into the effectiveness of ESL in clinical practice to date, with over 2000 patients included in the study population, 8 similar to the total number of patients recruited into ESL clinical trials (approximately 2400 1 ) , and thereby providing strong evidence of how ESL performs in this setting. The size of the Euro-Esli cohort has allowed meaningful, statistically robust subanalyses to be conducted, providing further insights into the use of ESL in clinical practice. 8 Since evidence for the use of ESL as monotherapy in clinical practice is currently scarce, we present here the results of a subanalysis of data from patients included in Euro-Esli who were either treated with ESL as initial monotherapy, or converted to ESL monotherapy after initially receiving ESL as adjunctive therapy.
| MATERIAL AND ME THODS

| Study design
The Euro-Esli study was an exploratory, retrospective, pooled analysis of data from European clinical practice studies, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] conducted to audit the effectiveness, safety, and tolerability of ESL as an adjunctive treatment for focal-onset seizures in clinical practice, details of which have been published previously. 8 In brief, effectiveness was assessed after 3, 6, and 12 months of ESL treatment and at final follow-up, and safety and tolerability were assessed for the duration of ESL treatment. The study protocol was approved by the Ethics
Committee of Hospital Universitario y Politécnico La Fe, Valencia, Spain. 8 A subanalysis was conducted of data from patients included in
Euro-Esli who were treated with ESL as initial monotherapy and patients who were being treated with ESL monotherapy at the last visit. Corresponding data were assessed for patients treated initially with ESL as adjunctive therapy and for those who were being treated with ESL as adjunctive therapy at the last visit. In addition, a further subanalysis of patients treated initially with ESL as adjunctive therapy was conducted, to compare outcomes for patients who subsequently withdrew to ESL monotherapy with those who continued to receive ESL as adjunctive therapy throughout follow-up.
| Study population
The studies included in Euro-Esli had broad inclusion/exclusion criteria, in order to be representative of the variety of patients encountered in clinical practice. 8 The current analysis included all patients from Euro-Esli for whom the number of AEDs used initially and at the last visit was known.
| Study assessments
Effectiveness was evaluated by assessing responder and seizure freedom rates. Response was defined as ≥50% seizure frequency reduction from baseline (ie, prior to ESL initiation), and seizure freedom was defined as having no seizures since at least the prior visit (either 3 or 6 months, depending on the time point at which seizure freedom was assessed).
Safety and tolerability were assessed by the evaluation of adverse events (AEs) and rate of ESL discontinuation due to AEs, respectively. AEs of special interest (hyponatremia and rash) were specifically evaluated. AEs (including hyponatremia and rash) were classified by participating clinicians according to Medical Dictionary for Regulatory Activities definitions. Sodium levels were evaluated, when recorded.
| Statistical analyses
Details of the statistical methodology employed in Euro-Esli have been published previously. 8 The safety population was defined as all patients who initiated ESL treatment and the effectiveness population was defined as all patients who initiated ESL treatment and had at least one effectiveness assessment. There was great heterogeneity in the particular objectives of the studies included in the analysis and, thus, in the information each study reported. The current analysis attempted to combine the reported information in the most complete way possible. Missing data were not imputed, except in cross-sectional studies, in which the last visit data were captured and included in the established cutoff points (3, 6, or 12 months).
When the observation timepoint of a study did not match the established cutoff points, the following allocations were made: observations performed between 1.5 and <4.5 months were allocated to the 3-month visit; those performed between 4.5 and <9 months were allocated to the 6-month visit; and those performed between 9 and 15 months were allocated to the 12-month visit. A "final" variable was also created, in which the last observation of each patient was included, independently of the timepoint when it occurred.
Since this was an exploratory study, no hypothesis was defined. No systematic review of the individual patients was undertaken due to the heterogeneity of the individual samples and objectives of each study. Therefore, individual studies were not treated as clusters.
8
A descriptive analysis of quantitative and qualitative variables was performed. 8 For each variable, the total number of patients for whom the data in question were available was stated and this value was used as the denominator for analysis. Quantitative variables were described as mean, standard deviation (SD), median, minimum
and maximum values, together with the number of valid cases and confidence intervals (CIs) or interquartile range (25th percentile to 75th percentile). Qualitative variables (responder rate, seizure freedom rate, incidence of AEs, rate of discontinuation due to AEs)
were described as means of absolute frequencies and percentages.
In the sub-analysis of patients who were initially treated with ESL 
| Study population
Demographic and baseline characteristics of patients who received ESL as initial monotherapy and monotherapy at the last visit are summarized in In the subanalysis of patients who were treated with ESL as initial adjunctive therapy, there were significant differences in demographic and baseline characteristics between patients who withdrew to ESL monotherapy compared with those who received ESL as adjunctive therapy throughout follow-up ( 
| ESL treatment
In the majority of patients, ESL was initiated due to lack of effectiveness of previous treatment and/or adverse reaction(s) to previous treatment (Table 1 ). In the subanalysis of patients treated with ESL as initial adjunctive therapy, there was a significant difference between patients who did versus did not withdraw to ESL monotherapy in TA B L E 1 (Continued) the reasons for initiating ESL treatment ( apy, reasons for ESL discontinuation were AEs (9.6%; n = 8), lack of efficacy (3.6%; n = 3), other (3.6%; n = 3), and unknown (1.2%; n = 1).
Among patients who received ESL as monotherapy at the last visit, reasons for ESL discontinuation comprised AEs (4.4%; n = 10), lack of efficacy (2.2%; n = 5), AEs and lack of efficacy (0.4%; n = 1), and other (1.8%; n = 4). decision (n = 9) and lack of compliance (n = 3)]) and unknown (3.0%; n = 57). Among those who received ESL as adjunctive therapy at the last visit, reasons for ESL discontinuation were AEs (9.6%; n = 106), lack of efficacy (8.4%; n = 93), AEs and lack of efficacy (4.7%; n = 52), other (1.9%; n = 21 [most commonly, patient decision (n = 8) and lack of compliance (n = 2)]), and unknown (0.7%; n = 8).
| Effectiveness
Responder rates in patients who received ESL as initial monotherapy Figure 1D ).
In the subanalysis of patients who received ESL as initial adjunctive therapy, responder and seizure freedom rates were significantly higher in patients who withdrew to monotherapy compared with those who received ESL as adjunctive therapy throughout follow-up, at all timepoints (P < 0.001 for all comparisons; Figure 2 ).
| Safety and tolerability
A summary of AEs and AEs leading to discontinuation is presented in The most commonly reported AEs (≥5% of patients in any group)
were dizziness, somnolence, instability/ataxia and fatigue, and the most commonly reported AEs leading to discontinuation (≥2% of patients in any group) were dizziness and fatigue. In patients who received ESL as monotherapy, either as initial treatment or at the last visit, no individual AE led to discontinuation of ≥2% of patients.
The incidences of hyponatremia and rash were low, although, in general, slightly higher in patients who received ESL as adjunctive therapy versus monotherapy (Table 4) . Similarly, hyponatremia
and rash led to discontinuation of a low proportion of patients (<2% across subgroups), although the rates of discontinuation were higher 
| D ISCUSS I ON
Euro-Esli is the largest ESL clinical practice study conducted to date. This hypothesis is supported by the findings of a previous subanalysis of Euro-Esli data, which demonstrated that responder and seizure rates were higher in patients treated with less than two versus two or more concomitant AEDs, where the number of concomitant AEDs was employed as a marker for treatment refractoriness. 8 It is also notable that the incidence of psychiatric comorbidity at baseline was higher in patients who received ESL as monotherapy than in those who received ESL as adjunctive therapy. Although the reasons for this are unclear, it might be hypothesized that clinicians specifically chose ESL as monotherapy for patients with psychiatric comorbidity, since it is associated with fewer psychiatric side effects than some other AEDs (eg, levetiracetam, topiramate, valproate). 1, [22] [23] [24] In terms of ESL dosing, it is important to point out that baseline dose levels used for ESL monotherapy and adjunctive therapy were only accurate for those patients initiating treatment with monother- in those who received ESL as adjunctive therapy, primarily because a higher proportion of patients treated with ESL as adjunctive therapy discontinued due to lack of efficacy. These findings again support the idea that patients who received ESL as adjunctive therapy were more refractory to treatment than those treated with ESL as monotherapy.
The proportion of patients treated with ESL as monotherapy increased from 4.3% at baseline to 17.1% at the last visit, consistent with the significant reduction in the number of concomitant AEDs patients used at the last visit, compared with baseline, previously reported for the overall Euro-Esli population. 8 The decrease in use of concomitant AEDs and associated increase in the proportion of patients treated with monotherapy following ESL initiation are encouraging, since it is recommended that polytherapy levels be reduced wherever possible, due to the potentially increased risk of pharmacokinetic interactions and toxicity associated with an increased drug burden. [25] [26] [27] The study's findings appear to support the value of such a recommendation, because although the incidence of AEs was similar regardless of whether ESL was used as monotherapy or adjunctive therapy, the rate of ESL discontinuation due to AEs was lower in patients treated with ESL monotherapy at the last visit, compared with those treated with adjunctive therapy at the last visit. This may therefore reflect an improvement in overall tolerability as patients withdrew from AED polytherapy to monotherapy (since the majority of patients treated with ESL monotherapy at the last visit had previously received concomi-
tant AED treatment[s] prior to withdrawing to ESL monotherapy).
This idea is supported by the results of the subanalysis of patients who received ESL as initial adjunctive therapy, since the rate of ESL discontinuation was significantly lower in patients who did versus did not withdraw to ESL monotherapy. These findings are consistent with those of a previous Euro-Esli subanalysis, which demonstrated that the incidence of AEs leading to discontinuation (as well as the overall incidence of AEs) was significantly lower in patients treated with less than two concomitant AEDs than in those treated with two or more concomitant AEDs. 8 In the current study, the most commonly reported AEs (dizziness, somnolence, instability/ataxia, fatigue) and AEs leading to discontinuation (dizziness and fatigue) were generally typical of those associated with sodium channel modulation (ESL's primary mechanism of action) and consistent with ESL's known safety profile. 1, 26 For example, in the phase III monotherapy trial conducted in patients with newly diagnosed epilepsy, the most frequently reported ESL-related AEs (≥5% of patients) were dizziness, headache, somnolence, and fatigue, and the AEs that most frequently led to ESL discontinuation (≥1% of patients) were fatigue, nausea, dizziness, somnolence, and rash. 2 Combining drugs that block voltage-dependent sodium channels is known to increase the likelihood of neurotoxic side effects (such as dizziness). 26 Therefore, it is perhaps unsurprising that the incidence of AEs leading to discontinuation was higher when ESL was used as adjunctive therapy versus monotherapy, since sodium channel blocking is the most common mechanism of at the last visit (90.4%) and patients who withdrew from ESL adjunctive therapy to ESL monotherapy (92.9%) in the current analysis were substantially higher than the responder rates observed in the phase III withdrawal to monotherapy trials (32.2%-46.0% during 10-week monotherapy treatment periods). 3, 4 These findings are perhaps unsurprising since the phase III withdrawal to monotherapy trials was conducted using a design in which baseline concomitant AEDs were down-titrated and withdrawn regardless of patients' prior response to treatment or clinical characteristics, and which therefore differed fundamentally from the individualized approach to treatment used in clinical practice (ie, as used in the studies included in Euro-Esli).
The similar seizure freedom rates observed in the current study and the phase III trial of ESL as initial monotherapy in patients with newly diagnosed focal-onset seizures 2 may nevertheless provide further evidence to suggest that the patients treated with ESL monotherapy in Euro-Esli were likely to have mostly comprised newly diagnosed patients, rather than patients with more long-standing, refractory focal epilepsy.
The findings of the study are also consistent with those of a recent multicenter, prospective, clinical practice study, conducted in 17 hospitals in Spain, in which 117 patients with focal seizures, aged 9-87 years, were treated with ESL monotherapy. 28 The responder rates (where response was defined as ≥50% seizure frequency reduction) after 3, 6, and 12 months were 82.0%, 79.7% 83.0%, respectively 28 (the corresponding responder rates in patients who received monotherapy at the last visit in the current study were 83.0%, 90.7%, and 93.2%, respectively, and in those who withdrew from ESL adjunctive therapy to ESL monotherapy, the corresponding values were 84.4%, 91.7%, and 94.1%, respectively). AEs were reported by 15.3% of patients and those reported by more than one patient comprised instability and dizziness (n = 9), somnolence (n = 3), and mild hyponatremia (n = 3). 28 It is difficult to directly compare the findings of the current analyses with those of studies that have assessed the effectiveness of monotherapy with other AEDs in clinical practice, primarily due to differences in study designs and patient populations. Some studies in those who converted to lacosamide monotherapy from another AED, and the corresponding 12-month seizure freedom rates were 60.2% and 52.5%, respectively. 31 Even considering the limited comparability of these studies to the current data, ESL seems to be at least as effective as other sodium channel blockers.
The current analyses were limited because the monotherapy and adjunctive therapy subgroups were not "pure" throughout the duration of follow-up, since some patients initially treated with monotherapy or adjunctive therapy converted to adjunctive therapy or monotherapy, respectively, during the course of the study, but were included in the subgroup to which they were initially allocated for the purposes of "initial treatment" analyses. Similarly, some of the patients treated with monotherapy and adjunctive therapy at the last visit were previously treated with adjunctive therapy and monotherapy, respectively, but were included in the subgroup that applied to them at the last visit (ie, monotherapy or adjunctive therapy) for all the "treatment at last visit" analyses.
These limitations are, however, vindicated by the results of the subanalysis of patients treated initially with ESL adjunctive therapy who did and did not subsequently withdraw to ESL monotherapy, since these were consistent with the other findings of the study.
As with the overall Euro-Esli study, 8 the study has additional limitations, primarily because it was a subanalysis of a retrospective pooled analysis. Moreover, there was great heterogeneity in the studies included in Euro-Esli, and although individual patient data were previously reviewed by the authors of the individual studies, they were not reviewed systematically post hoc. 8 The heterogeneous nature of the studies included in Euro-Esli also meant that, across all endpoints and assessments, data were not available for all patients at all timepoints. However, the large number of patients included in Euro-Esli allowed a meaningful number of patients to be assessed in the current analysis, mitigating some of these limitations.
In summary, taking into account the aforementioned limitations, these findings provide further evidence supporting the use of ESL as monotherapy, as well as adjunctive therapy, for focal-onset seizures, complementing evidence from regulatory clinical trials.
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